Ankur Pandya

Ankur Pandya

Auto-generated profile, based on publicly available information

Ankur Pandya

Department of Health Policy and Management Harvard T.H. Chan School of Public Health Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2015 in JAMA
Verified
Journal Article
Open access
PDF file
APAnkur Pandya
Ankur Pandya
SSStephen Sy
Stephen Sy
SCSylvia Cho
Sylvia Cho
MWMilton C. Weinstein
Milton C. Weinstein
TGThomas A. Gaziano
Thomas A. Gaziano
In November 2013 the American College of Cardiology and the American Heart Association (ACC/AHA) released new recommendations to guide statin treatment initiation for the primary prevention of cardiovascular disease.1 These guidelines were a departure from previous recommendations,2 most notably for deemphasizing low-density lipoprotein (LDL) cholesterol thresholds to focus on total atherosclerotic cardiovascular disease (ASCVD) risk, which is defined by new Pooled Cohort Equations.3 The ACC/AHA guidelines established 4 categories for statin treatment eligibility for adults aged 40 to 75 years, including 10-year ASCVD risk of 7.5% or higher. Based on the new ASCVD risk threshold, Pencina et al4 estimated that 8.2 million additional adults in the United States would be recommended for statin treatment compared with previous recommendations.

13 May 2021 in Stroke
Verified
Journal Article
Closed access
PDF file
HKHooman Kamel
Hooman Kamel
NPNeal Parikh
Neal Parikh
ACAbhinaba Chatterjee
Abhinaba Chatterjee
LKLuke K. Kim
Luke K. Kim
JSJeffrey L Saver
Jeffrey L Saver
BNBabak B. Navi
Babak B. Navi
Background and Purpose: Mechanical thrombectomy helps prevent disability in patients with acute ischemic stroke involving occlusion of a large cerebral vessel. Thrombectomy requires procedural expertise and not all hospitals have the staff to perform this intervention. Few population-wide data exist regarding access to mechanical thrombectomy. Methods: We examined access to thrombectomy for ischemic stroke using discharge data from calendar years 2016 to 2018 from all nonfederal emergency departments and acute care hospitals across 11 US states encompassing 80 million residents. Facilities were classified as hubs if they performed mechanical thrombectomy, gateways if they transferred patients who ultimately underwent mechanical thrombectomy, and gaps otherwise. We used standard descriptive statistics and unadjusted logistic regression models in our primary analyses. Results: Among 205 681 patients with ischemic stroke, 100 139 (48.7% [95% CI, 48.5%–48.9%]) initially received care at a thrombectomy hub, 72 534 (35.3% [95% CI, 35.1%–35.5%]) at a thrombectomy gateway, and 33 008 (16.0% [95% CI, 15.9%–16.2%]) at a thrombectomy gap. Patients who initially received care at thrombectomy gateways were substantially less likely to ultimately undergo thrombectomy than patients who initially received care at thrombectomy hubs (odds ratio, 0.27 [95% CI, 0.25–0.28]). Rural patients had particularly limited access: 27.7% (95% CI, 26.9%–28.6%) of such patients initially received care at hubs versus 69.5% (95% CI, 69.1%–69.9%) of urban patients. For 93.8% (95% CI, 93.6%–94.0%) of patients with stroke at gateways, their initial facility was capable of delivering intravenous thrombolysis, compared with 76.3% (95% CI, 75.8%–76.7%) of patients at gaps. Our findings were unchanged in models adjusted for demographics and comorbidities and persisted across multiple sensitivity analyses, including analyses adjusting for estimated stroke severity. Conclusions: We found that a substantial proportion of patients with ischemic stroke across the United States lacked access to thrombectomy even after accounting for interhospital transfers. US systems of stroke care require further development to optimize thrombectomy access.

6 January 2022 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
PDF file
APAnkur Pandya
Ankur Pandya
YYYuan-Jui Yu
Yuan-Jui Yu
YGYin Ge
Yin Ge
ENEike Nagel
Eike Nagel
RKRaymond Y. Kwong
Raymond Y. Kwong
SKSebastian Kelle
Sebastian Kelle
Although prior reports have evaluated the clinical and cost impacts of cardiovascular magnetic resonance (CMR) for low-to-intermediate-risk patients with suspected significant coronary artery disease (CAD), the cost-effectiveness of CMR compared to relevant comparators remains poorly understood. We aimed to summarize the cost-effectiveness literature on CMR for CAD and create a cost-effectiveness calculator, useable worldwide, to approximate the cost-per-quality-adjusted-life-year (QALY) of CMR and relevant comparators with context-specific patient-level and system-level inputs. We searched the Tufts Cost-Effectiveness Analysis Registry and PubMed for cost-per-QALY or cost-per-life-year-saved studies of CMR to detect significant CAD. We also developed a linear regression meta-model (CMR Cost-Effectiveness Calculator) based on a larger CMR cost-effectiveness simulation model that can approximate CMR lifetime discount cost, QALY, and cost effectiveness compared to relevant comparators [such as single-photon emission computed tomography (SPECT), coronary computed tomography angiography (CCTA)] or invasive coronary angiography. CMR was cost-effective for evaluation of significant CAD (either health-improving and cost saving or having a cost-per-QALY or cost-per-life-year result lower than the cost-effectiveness threshold) versus its relevant comparator in 10 out of 15 studies, with 3 studies reporting uncertain cost effectiveness, and 2 studies showing CCTA was optimal. Our cost-effectiveness calculator showed that CCTA was not cost-effective in the US compared to CMR when the most recent publications on imaging performance were included in the model. Based on current world-wide evidence in the literature, CMR usually represents a cost-effective option compared to relevant comparators to assess for significant CAD.

15 May 2018 in JAMA
Verified
Journal Article
Open access
PDF file
APAnkur Pandya
Ankur Pandya
This Viewpoint points out that many definitions of low-value health care are based exclusively on efficacy or harm, and argues that inclusion of cost and cost-e

1 August 2020 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
ASAferdita Spahillari
Aferdita Spahillari
JZJinyi Zhu
Jinyi Zhu
BFBart S. Ferket
Bart S. Ferket
MHM. G. Myriam Hunink
M. G. Myriam Hunink
JCJ. Jeffrey Carr
J. Jeffrey Carr
APAnkur Pandya
Ankur Pandya
African American individuals have a greater incidence of atherosclerotic cardiovascular disease (ASCVD) compared with white individuals1 yet are less likely to receive guideline-recommended statin therapy.2 Beliefs regarding statin safety and effectiveness,2 along with reports raising concerns about statin overtreatment owing to risk overestimation in African American and white individuals with predicted 10-year ASCVD risk of 7.5% or higher,3 may result in reluctance of patients to adhere to statin therapy. To this end, the 2018 American College of Cardiology/American Heart Association (ACC/AHA) guidelines4 recommend consideration of a non-0 coronary artery calcium (CAC) score to guide statin therapy for primary ASCVD prevention in adults with an intermediate risk for ASCVD and no other risk factors that automatically lead to statin therapy indication (eg, diabetes) (Figure 1).

29 August 2018 in BMC Medicine
Verified
Journal Article
Open access
PDF file
APAnkur Pandya
Ankur Pandya
TDTim Doran
Tim Doran
JZJinyi Zhu
Jinyi Zhu
SWSimon Walker
Simon Walker
EAEmily Arntson
Emily Arntson
ARAndrew M. Ryan
Andrew M. Ryan
Introduced in 2004, the United Kingdom’s (UK) Quality and Outcomes Framework (QOF) is the world’s largest primary-care pay-for-performance programme. Given some evidence of the benefits and the substantial costs associated with the QOF, it remains unclear whether the programme is cost-effective. Therefore, we assessed the cost-effectiveness of continuing versus stopping the QOF. We developed a lifetime simulation model to estimate quality-adjusted life years (QALYs) and costs for a UK population cohort aged 40–74 years (n = 27,070,862) exposed to the QOF and for a counterfactual scenario without exposure. Based on a previous retrospective cross-country analysis using data from 1994 to 2010, we assumed the benefits of the QOF to be a change in age-adjusted mortality of −3.68 per 100,000 population (95% confidence interval –8.16 to 0.80). We used cost-effectiveness thresholds of £30,000/QALY, £20,000/QALY and £13,000/QALY to determine the optimal strategy in base-case and sensitivity analyses. In the base-case analysis, continuing the QOF increased population-level QALYs and health-care costs yielding an incremental cost-effectiveness ratio (ICER) of £49,362/QALY. The ICER remained >£30,000/QALY in scenarios with and without non-fatal outcomes or increased drug costs, and under differing assumptions about the duration of QOF benefit following its hypothetical discontinuation. The ICER for continuing the programme fell below £30,000/QALY when QOF incentive payments were 36% lower (while preserving QOF mortality benefits), and in scenarios where the QOF resulted in substantial reductions in health-care spending or non-fatal cardiovascular disease events. Continuing the QOF was cost-effective in 18%, 3% and 0% of probabilistic sensitivity analysis iterations using thresholds of £30,000/QALY, £20,000/QALY and £13,000/QALY, respectively. Compared to stopping the QOF and returning all associated incentive payments to the National Health Service, continuing the QOF is not cost-effective. To improve population health efficiently, the UK should redesign the QOF or pursue alternative interventions.